2023-505908-28-00CompletedPhase 1
A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 17 May 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (actual)
- First submitted
- 27 Sept 2024
- Start date
- 26 Feb 2025
- Lead sponsor
- Laboratorios Liomont S.A. de C.V.
- Diseases
- Asthma
- EU CT number
- 2023-505908-28-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 68
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital de la Santa Creu i Sant Pau | Barcelona | Spain | Completed |
| Hospital del Mar | Barcelona | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.